Capricor Therapeutics, Inc. (NASDAQ:CAPR) belongs to Healthcare sector. Its weekly performance is -2.50%. On last trading day company shares ended up $4.68. Capricor Therapeutics, Inc. (NASDAQ:CAPR) distance from 50-day simple moving average (SMA50) is -22.39%. On 17 June, Capricor Therapeutics, Inc. (NASDAQ:CAPR) announced the appointment of Houman Hemmati, M.D., Ph.D. to the newly created position of Vice President of Medical and Clinical Development for New Therapies. In this role, Dr. Hemmati will work to drive promising new therapies such as Capricor’s exosome platform into clinical development as he works closely with the R&D, manufacturing and product development teams.
Aegle Therapeutics receives IND clearance from FDA for stem cell-derived extracellular vesicle therapy
11 days ago
Avalon GloboCare Forms Joint Laboratory with Top-Ranked Hospital in Shanghai for Regenerative Exosomics
26 days ago
ZenBio, Inc. Awarded a Phase I SBIR Grant for Tuned Stem Cell Extracellular Vesicles as a Novel Chronic Wound Therapeutic
April 27, 2018